| __timestamp | Ligand Pharmaceuticals Incorporated | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 1499100000 |
| Thursday, January 1, 2015 | 24378000 | 1923500000 |
| Friday, January 1, 2016 | 26621000 | 2351400000 |
| Sunday, January 1, 2017 | 28653000 | 2564000000 |
| Monday, January 1, 2018 | 37734000 | 2397300000 |
| Tuesday, January 1, 2019 | 41884000 | 2503400000 |
| Wednesday, January 1, 2020 | 64435000 | 3344600000 |
| Friday, January 1, 2021 | 57483000 | 4529200000 |
| Saturday, January 1, 2022 | 70062000 | 4179100000 |
| Sunday, January 1, 2023 | 52790000 | 4650100000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding operational efficiency is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Over this period, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023, a staggering 6,500% more than Ligand's $52.79 million. Ligand Pharmaceuticals, while smaller in scale, demonstrated a more stable SG&A trend, with expenses increasing by about 133% from 2014 to 2022. In contrast, Viatris saw a 210% rise in the same timeframe. This disparity highlights the differing operational strategies and market positions of these companies. As investors and analysts look to the future, understanding these trends can provide valuable insights into each company's financial health and strategic direction.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.
Jazz Pharmaceuticals plc and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Who Optimizes SG&A Costs Better? Xenon Pharmaceuticals Inc. or Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Merus N.V. vs Ligand Pharmaceuticals Incorporated
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Galapagos NV